Lipum AB (publ) has published the interim report for period January to March for 2023. Below is a summary, a complete report (only in Swedish) is available on the company's website.

CEO Einar Pontén comments: “I am excited about our ongoing Phase 1 clinical trial of the drug candidate SOL-116 as everything is going according to plan.”

Financial summary January – March 2023

  • Net sales: KSEK 0 (0)
  • Result after financial items: KSEK -7,173 (-5,830)
  • Cash and cash equivalents as of March 31: KSEK 26,765 (27,971)

Significant events during the period January – March 2023

  • The ongoing clinical phase 1 study with the drug candidate SOL-116 is progressing as planned after dosing four groups of healthy subjects.

Significant events after the period

  • Carl-Johan Spak was nominated as new board member of Lipum AB.

CEO Einar Pontén comments on the report in a live webcast on April 25 at 09:00, link.

Contacts
Einar Pontén, CEO
E-post: einar.ponten@lipum.se
Mobile: +46 70 578 34 95
Web: www.lipum.se

About Us
Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

Attachments
Lipum AB – Kvartalsrapport Januari Mars 2023

Lipum AB – Kvartalsrapport Januari Mars 2023